Karyopharm Therapeutics (KPTI) Income towards Parent Company (2012 - 2025)

Karyopharm Therapeutics has reported Income towards Parent Company for 14 years, with the latest figure at $90.2 million in Q4 2025.

• For the quarter ending Q4 2025, Income towards Parent Company rose 97.49% year-over-year to $90.2 million; the trailing twelve-month figure through Dec 2025 stood at -$3.7 million (down 15995.65% YoY), and the FY2025 full-year result was -$3.7 million, down 15995.65% from the prior year.
• Income towards Parent Company for Q4 2025 stood at $90.2 million, up from -$33.1 million in the prior quarter.
• The five-year high for Income towards Parent Company was $90.2 million in Q4 2025, with the low at -$57.4 million in Q1 2021.
• Historically, Income towards Parent Company has averaged -$20.3 million across 5 years, with a median of -$35.4 million in 2022.
• Annual changes were most pronounced in 2024 — Income towards Parent Company soared 209.21% — and 2025, when it slumped 256.57%.
• Karyopharm Therapeutics' Income towards Parent Company stood at $68.8 million in 2021, then slumped by 155.99% to -$38.5 million in 2022, then declined by 8.59% to -$41.8 million in 2023, then soared by 209.21% to $45.7 million in 2024, then jumped by 97.49% to $90.2 million in 2025.
• The last three Income towards Parent Company figures came in at $90.2 million (Q4 2025), -$33.1 million (Q3 2025), and -$37.3 million (Q2 2025), per Business Quant data.